Literature DB >> 18479880

Pharmacokinetic study of matrine, oxymatrine and oxysophocarpine in rat plasma after oral administration of Sophora flavescens Ait. extract by liquid chromatography tandem mass spectrometry.

Lei Zhang1, Wentao Liu, Ruowen Zhang, Zhiwei Wang, Zhenduo Shen, Xiaohui Chen, Kaishun Bi.   

Abstract

A rapid, sensitive and selective high-performance liquid chromatography tandem mass spectrometric method (HPLC-MS) has been developed and validated for the simultaneous determination of matrine (MT), oxymatrine (OMT) and oxysophocarpine (OSP) in rat plasma after oral administration of Sophora flavescens Ait. extract using pseudoephedrine hydrochloride as an internal standard (I.S.). The three analytes were extracted from the plasma samples by liquid-liquid extraction with chloroform. The chromatographic separation was accomplished on a Kromasil C18 column (150 mm x 4.6 mm). Detection was performed on a single quadrupole mass spectrometer by selected ion monitoring (SIM) mode via electrospray ionization (ESI) source. The total run time was 12 min between injections. The assay had a lower limit of quantification of 1.0 ng/ml for MT, 2.0 ng/ml for OMT and 2.0 ng/ml for OSP using 200 microl of plasma. The calibration curves were linear in the measured range. The overall precision and accuracy for all concentrations of quality controls and standards was better than 15%. The proposed method enables unambiguous identification and quantification of MT, OMT and OSP in vivo. This was the first report on determination of the major quinolizidine alkaloids in rat plasma after oral administration of Sophora flavescens Ait. extract. The results provided a meaningful basis for evaluating the clinical applications of the herbal medicine.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18479880     DOI: 10.1016/j.jpba.2008.03.019

Source DB:  PubMed          Journal:  J Pharm Biomed Anal        ISSN: 0731-7085            Impact factor:   3.935


  7 in total

1.  A novel matrine derivate inhibits differentiated human hepatoma cells and hepatic cancer stem-like cells by suppressing PI3K/AKT signaling pathways.

Authors:  Ying Liu; Yang Qi; Zhi-Hui Bai; Chen-Xu Ni; Qi-Hui Ren; Wei-Heng Xu; Jing Xu; Hong-Gang Hu; Lei Qiu; Jian-Zhong Li; Zhi-Gao He; Jun-Ping Zhang
Journal:  Acta Pharmacol Sin       Date:  2016-10-24       Impact factor: 6.150

2.  Physiologically based pharmacokinetics of matrine in the rat after oral administration of pure chemical and ACAPHA.

Authors:  Guanghua Gao; Francis C P Law
Journal:  Drug Metab Dispos       Date:  2009-01-08       Impact factor: 3.922

3.  Effects of matrine against the growth of human lung cancer and hepatoma cells as well as lung cancer cell migration.

Authors:  Ying Zhang; Hui Zhang; Pengfei Yu; Qian Liu; Kun Liu; Huiying Duan; Ginling Luan; Kazumi Yagasaki; Guoying Zhang
Journal:  Cytotechnology       Date:  2009-08-02       Impact factor: 2.058

4.  Biopharmaceutical and pharmacokinetic characterization of matrine as determined by a sensitive and robust UPLC-MS/MS method.

Authors:  Zhen Yang; Song Gao; Taijun Yin; Kaustubh H Kulkarni; Yang Teng; Ming You; Ming Hu
Journal:  J Pharm Biomed Anal       Date:  2009-11-26       Impact factor: 3.935

5.  Pharmacokinetic study of 14-(3-methylbenzyl)matrine and 14-(4-methylbenzyl)matrine in rat plasma using liquid chromatography-tandem mass spectrometry.

Authors:  Minjie Jiang; Lisheng Wang; Shulin Huang; Liba Xu; Chao Hu; Weizhe Jiang
Journal:  PLoS One       Date:  2015-02-25       Impact factor: 3.240

6.  Optimization of supercritical-CO2 extraction and pharmacokinetics in SD rats of alkaloids form Sophora moorcroftiana seed.

Authors:  Chunhui Hu; Xuehui Gan; Qiangqiang Jia; Pan Gao; Tao Du; Fabin Zhang
Journal:  Sci Rep       Date:  2022-02-28       Impact factor: 4.379

7.  Design and Synthesis of Molecular Hybrids of Sophora Alkaloids and Cinnamic Acids as Potential Antitumor Agents.

Authors:  Hai Shang; Lingyu Li; Liyan Ma; Yu Tian; Hongmei Jia; Tao Zhang; Meng Yu; Zhongmei Zou
Journal:  Molecules       Date:  2020-03-05       Impact factor: 4.411

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.